Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003790 · ClinicalTrials.gov registry record
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
A clinical trial, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 496
- Enrollment target
NCT00003790: Completed study, sponsored by Children's Oncology Group.
NCT00003790 is a clinical trial that has completed, run by Children's Oncology Group. The registered enrollment target is 496 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003790 has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 496 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures may improve the ability to detect residual disease. PURPOSE: Clinical trial to detect the presence of residual disease in children who are receiving therapy for acute myeloid leukemia or myelodysplastic syndrome.
Interventions
- GENETIC polymerase chain reaction
- OTHER flow cytometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 1995-02 |
| Est. Completion | 2006-09 |
What the finished NCT00003790 record still lists
NCT00003790 is an observational study that tracks outcomes without assigning an intervention. The registered 496 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which polymerase chain reaction is the first listed.
NCT00003790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003790 about?
NCT00003790 is a clinical study titled "Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome". RATIONALE: Diagnostic procedures may improve the ability to detect residual disease. PURPOSE: Clinical trial to detect the presence of residual disease in children who are receiving therapy for acute myeloid leukemia or myelodysplastic syndrome.
What is the current status of trial NCT00003790?
This trial is currently completed. The enrollment target is 496 participants. The study started on 1995-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00003790?
The interventions under investigation include: polymerase chain reaction (GENETIC), flow cytometry (OTHER).
Who is sponsoring clinical trial NCT00003790?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia